Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure

Hagop Kantarjian, Susan O'Brien, Moshe Talpaz, Gautam Borthakur, Farhad Ravandi, Stefan Faderl, Srdan Verstovsek, Mary Beth Rios, Jianqin Shan, Francis Giles, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

BACKGROUND. The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. METHODS. The outcome of 420 patients with CML post-imatinib failure (resistance-recurrence in 374; toxicities in 46) were reviewed in relation to survival, overall, and by different therapies. RESULTS. The estimated 3-year survival rates were 72% in 88 patients who progressed in chronic phase, 30% in 130 patients who progressed in accelerated phase, 7% in 156 patients who progressed in blastic phase, and 75% in 37 patients in chronic phase with imatinib intolerance. Survival in chronic phase was better when subsequent therapy was nilotinib or dasatinib vs allogeneic stem cell transplant vs others (estimated 2-year survival rates 100% vs 72% vs 67%; P = .01), but not in accelerated-blastic phase. CONCLUSIONS. Prognosis post-imatinib failure in chronic phase is reasonable; it is poor if the CML phase post-imatinib failure is accelerated or blastic.

Original languageEnglish (US)
Pages (from-to)1556-1560
Number of pages5
JournalCancer
Volume109
Issue number8
DOIs
StatePublished - Apr 15 2007
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Survival Rate
Leukemia, Myeloid, Chronic Phase
Survival
Imatinib Mesylate
Stem Cells
Therapeutics
Transplants
Recurrence

Keywords

  • Chronic myelogenous leukemia
  • Imatinib mesylate failure
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. / Kantarjian, Hagop; O'Brien, Susan; Talpaz, Moshe; Borthakur, Gautam; Ravandi, Farhad; Faderl, Stefan; Verstovsek, Srdan; Rios, Mary Beth; Shan, Jianqin; Giles, Francis; Cortes, Jorge.

In: Cancer, Vol. 109, No. 8, 15.04.2007, p. 1556-1560.

Research output: Contribution to journalArticle

Kantarjian, H, O'Brien, S, Talpaz, M, Borthakur, G, Ravandi, F, Faderl, S, Verstovsek, S, Rios, MB, Shan, J, Giles, F & Cortes, J 2007, 'Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure', Cancer, vol. 109, no. 8, pp. 1556-1560. https://doi.org/10.1002/cncr.22569
Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007 Apr 15;109(8):1556-1560. https://doi.org/10.1002/cncr.22569
Kantarjian, Hagop ; O'Brien, Susan ; Talpaz, Moshe ; Borthakur, Gautam ; Ravandi, Farhad ; Faderl, Stefan ; Verstovsek, Srdan ; Rios, Mary Beth ; Shan, Jianqin ; Giles, Francis ; Cortes, Jorge. / Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. In: Cancer. 2007 ; Vol. 109, No. 8. pp. 1556-1560.
@article{2024102370ae4220b1faf86e037f6452,
title = "Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure",
abstract = "BACKGROUND. The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. METHODS. The outcome of 420 patients with CML post-imatinib failure (resistance-recurrence in 374; toxicities in 46) were reviewed in relation to survival, overall, and by different therapies. RESULTS. The estimated 3-year survival rates were 72{\%} in 88 patients who progressed in chronic phase, 30{\%} in 130 patients who progressed in accelerated phase, 7{\%} in 156 patients who progressed in blastic phase, and 75{\%} in 37 patients in chronic phase with imatinib intolerance. Survival in chronic phase was better when subsequent therapy was nilotinib or dasatinib vs allogeneic stem cell transplant vs others (estimated 2-year survival rates 100{\%} vs 72{\%} vs 67{\%}; P = .01), but not in accelerated-blastic phase. CONCLUSIONS. Prognosis post-imatinib failure in chronic phase is reasonable; it is poor if the CML phase post-imatinib failure is accelerated or blastic.",
keywords = "Chronic myelogenous leukemia, Imatinib mesylate failure, Prognosis",
author = "Hagop Kantarjian and Susan O'Brien and Moshe Talpaz and Gautam Borthakur and Farhad Ravandi and Stefan Faderl and Srdan Verstovsek and Rios, {Mary Beth} and Jianqin Shan and Francis Giles and Jorge Cortes",
year = "2007",
month = "4",
day = "15",
doi = "10.1002/cncr.22569",
language = "English (US)",
volume = "109",
pages = "1556--1560",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Talpaz, Moshe

AU - Borthakur, Gautam

AU - Ravandi, Farhad

AU - Faderl, Stefan

AU - Verstovsek, Srdan

AU - Rios, Mary Beth

AU - Shan, Jianqin

AU - Giles, Francis

AU - Cortes, Jorge

PY - 2007/4/15

Y1 - 2007/4/15

N2 - BACKGROUND. The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. METHODS. The outcome of 420 patients with CML post-imatinib failure (resistance-recurrence in 374; toxicities in 46) were reviewed in relation to survival, overall, and by different therapies. RESULTS. The estimated 3-year survival rates were 72% in 88 patients who progressed in chronic phase, 30% in 130 patients who progressed in accelerated phase, 7% in 156 patients who progressed in blastic phase, and 75% in 37 patients in chronic phase with imatinib intolerance. Survival in chronic phase was better when subsequent therapy was nilotinib or dasatinib vs allogeneic stem cell transplant vs others (estimated 2-year survival rates 100% vs 72% vs 67%; P = .01), but not in accelerated-blastic phase. CONCLUSIONS. Prognosis post-imatinib failure in chronic phase is reasonable; it is poor if the CML phase post-imatinib failure is accelerated or blastic.

AB - BACKGROUND. The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. METHODS. The outcome of 420 patients with CML post-imatinib failure (resistance-recurrence in 374; toxicities in 46) were reviewed in relation to survival, overall, and by different therapies. RESULTS. The estimated 3-year survival rates were 72% in 88 patients who progressed in chronic phase, 30% in 130 patients who progressed in accelerated phase, 7% in 156 patients who progressed in blastic phase, and 75% in 37 patients in chronic phase with imatinib intolerance. Survival in chronic phase was better when subsequent therapy was nilotinib or dasatinib vs allogeneic stem cell transplant vs others (estimated 2-year survival rates 100% vs 72% vs 67%; P = .01), but not in accelerated-blastic phase. CONCLUSIONS. Prognosis post-imatinib failure in chronic phase is reasonable; it is poor if the CML phase post-imatinib failure is accelerated or blastic.

KW - Chronic myelogenous leukemia

KW - Imatinib mesylate failure

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=34247248807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247248807&partnerID=8YFLogxK

U2 - 10.1002/cncr.22569

DO - 10.1002/cncr.22569

M3 - Article

C2 - 17342766

AN - SCOPUS:34247248807

VL - 109

SP - 1556

EP - 1560

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -